ImmunityBio
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 2014-01-01
- Employees
- 628
- Market Cap
- $2.9B
- Website
- http://www.immunitybio.com
- Introduction
ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.
Expanded Access Use of Nogapendekin-alfa Inbakicept in the Reversal and Maintenance of Absolute Lymphocyte Count (ALC) for the Treatment of Lymphopenia Induced by Chemotherapy, Immunotherapy, and/or Radiation Therapy
- Conditions
- Lymphopenia
- First Posted Date
- 2025-05-04
- Last Posted Date
- 2025-06-18
- Lead Sponsor
- ImmunityBio, Inc.
- Registration Number
- NCT06956547
- Locations
- 🇺🇸
Chan Soon - Shiong Institute for Medicine, El Segundo, California, United States
Clinical Trial of Ablation Therapy in Participants With Intermediate-Risk Non-Muscle Invasive Papillary Bladder Cancer
- Conditions
- Non-muscle Invasive Bladder Cancer (NMIBC)
- Interventions
- Drug: N-803 and Gemcitabine
- First Posted Date
- 2025-02-17
- Last Posted Date
- 2025-02-17
- Lead Sponsor
- ImmunityBio, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT06829823
ResQ132EX-NMIBC: Expanded Access Use of Recombinant Bacillus Calmette-Guérin in Nonmuscle Invasive Bladder Cancer
- Conditions
- NMIBC
- First Posted Date
- 2025-02-05
- Last Posted Date
- 2025-05-31
- Lead Sponsor
- ImmunityBio, Inc.
- Registration Number
- NCT06810141
- Locations
- 🇺🇸
University Urology, Mobile, Alabama, United States
🇺🇸Sebring Urology Center, Sebring, Florida, United States
🇺🇸Florida Urology Partners, Tampa, Florida, United States
ResQ133A-NMIBC: Intravesical Recombinant Mycobacterium (rMBCG) in Participants With NMIBC Eligible to Receive Intravesical Tice BCG
- Conditions
- NMIBC
- Interventions
- Biological: Intravesical Recombinant Mycobacterium (rMBCG)
- First Posted Date
- 2025-01-30
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- ImmunityBio, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT06800963
- Locations
- 🇺🇸
OPN Healthcare, INC, Glendale, California, United States
🇺🇸Cancer & Blood Specialty Clinic, Los Alamitos, California, United States
Immunotherapy Before and After Surgery
- Conditions
- High-risk Prostate Cancer
- Interventions
- First Posted Date
- 2025-01-09
- Last Posted Date
- 2025-05-04
- Lead Sponsor
- ImmunityBio, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT06765902
Immunotherapy With N 803, ETBX-071, and M-CENK in Combination With Radiation for Participants With High-Risk Prostate Cancer.
- Conditions
- High-risk Prostate Cancer
- Interventions
- Drug: N-803 (IL-15 Superagonist)Drug: ETBX-071 (PSA-based Oncolytic Virus)Drug: M-CENK (Activated NK Cells)Radiation: External Beam Radiation Therapy (EBRT)Radiation: Androgen Deprivation Therapy (ADT)Radiation: Post-radiation immunotherapy
- First Posted Date
- 2025-01-09
- Last Posted Date
- 2025-05-06
- Lead Sponsor
- ImmunityBio, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT06765954
ResQ201A: Clinical Trial Of N-803 Plus TISLELIZUMAB And DOCETAXEL Versus DOCETAXEL Monotherapy In Participants With Advanced Or Metastatic Non-Small Cell Lung Cancer
- First Posted Date
- 2024-12-20
- Last Posted Date
- 2025-05-06
- Lead Sponsor
- ImmunityBio, Inc.
- Target Recruit Count
- 460
- Registration Number
- NCT06745908
- Locations
- 🇺🇸
OPN Healthcare INC, Glendale, California, United States
🇺🇸OPN Healthcare INC/ Cancer and Blood Specialty Clinic, Los Alamitos, California, United States
A Phase 2, Open-label, Single-arm Study of Autologous M-CENK Adoptive Cell Therapy and N-803 (IL-15 Superagonist) in Combination with Gemcitabine in Participants with Recurrent Platinum-Resistant High-Grade Ovarian Cancer
- Conditions
- Platinum-resistant Ovarian Cancer
- Interventions
- First Posted Date
- 2024-11-29
- Last Posted Date
- 2025-02-13
- Lead Sponsor
- ImmunityBio, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT06710288
- Locations
- 🇺🇸
Chan Soon-Shiong Institute for Medicine, El Segundo, California, United States
Study for Subjects with Relapsed/Refractory Non-Hodgkin Lymphoma
- Conditions
- Non-Hodgkin Lymphoma Refractory/ Relapsed
- Interventions
- First Posted Date
- 2024-03-28
- Last Posted Date
- 2025-01-14
- Lead Sponsor
- ImmunityBio, Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT06334991
- Locations
- 🇿🇦
FARMOVS, Bloemfonteun, Free State, South Africa
🇿🇦Dr. Jackie Thomson Inc., Johannesburg, Gauteng, South Africa
🇿🇦Albert Cellular Therapy, Pretoria, Gauteng, South Africa
N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive Glioblastoma
- First Posted Date
- 2023-09-29
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- ImmunityBio, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT06061809
- Locations
- 🇺🇸
Providence Medical Foundation, Fullerton, California, United States
🇺🇸Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States